Cepheid Logo
Request Info
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Request Info
Request Info

Xpert® vanA

Order Now
Van A computer generated depiction.

On-demand testing to assist with VRE surveillance in around 48 minutes. Positive results in as soon as 45 minutes with Early Assay Termination (EAT).

The Need

an ill woman listens to a physician
  • Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
  • In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
  • High-risk patients colonized with VRE have 24 times increased infection risk2
  • Infections caused by VRE are associated with high mortality3
  • VRE has an impact on patient length-of-stay, and in turn, hospitalization costs3
1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023

2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.

3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

The Solution

a male and a female researchers scanning cepheid test cartridges
  • The Xpert vanA test is a rapid molecular detection of the vanA gene associated with VRE colonization risk to aid in the recognition, prevention, and control of vancomycin-resistant organisms that colonize patients in healthcare settings
  • Fast, active screening of high-risk patients to support infection control measures in healthcare settings4
4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663

The Impact

a smiling female doctor attends an elderly woman
Published studies have reported improved infection control workflows following implementation of rapid molecular screening5
  • 93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h
  • High negative predictive value allows for better management of non-colonized patients
  • Associated with a reduction in the number of identified contact patients
Published studies have reported reductions in isolation days following implementation of rapid vanA screening6:
  • 141 saved isolation days and 292 saved transmission risk days
5 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov 2:30.

6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59

* 1€=1.09$, conversion rate December 15th 2023

Connect To Better Outcomes

Request Info

Insights

Get More Insights